2 Information about axicabtagene ciloleucel

Marketing authorisation indication

2.1 Axicabtagene ciloleucel (Yescarta, Kite) is 'indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or more lines of systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for axicabtagene ciloleucel.


2.3 The list price for axicabtagene ciloleucel is £280,451 per single infusion bag (approximately 68 ml, company submission).

2.4 The company has a commercial arrangement. This makes axicabtagene ciloleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)